Enodia Therapeutics and Pfizer inked a research collaboration and licensing deal to discover and develop small-molecule inhibitors of Sec61. Enodia will run discovery and early optimization while Pfizer takes over clinical, manufacturing, regulatory, and commercial activities. The agreement includes an upfront payment plus development and sales milestones, with total potential value exceeding $500 million, positioning Sec61 as a new targeted protein-degradation-adjacent entry point. Separately, Viatris agreed to acquire Pacira BioSciences in a deal valued at about $1.65 billion, adding established non-opioid analgesic products Exparel and Zilretta to Viatris’ portfolio—an example of continued consolidation around revenue-generating assets.